Literature DB >> 19140758

Better adherence with once-daily antiretroviral regimens: a meta-analysis.

Jean-Jacques Parienti1, David R Bangsberg, Renaud Verdon, Edward M Gardner.   

Abstract

Once-daily regimens of antiretroviral therapy are simpler than other regimens, but whether such regimens are associated with better adherence to treatment is controversial. We performed a meta-analysis of 11 randomized, controlled trials (total number of subjects, 3029), which revealed that the adherence rate was better with once-daily regimens (+2.9%; 95% confidence interval, 1.0%-4.8%; P < .003) than with twice-daily regimens. This modest effect was more pronounced at the time of treatment initiation and for regimens for which all medications were taken once per day.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19140758      PMCID: PMC2708315          DOI: 10.1086/596482

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

2.  The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials.

Authors:  Sharon Mannheimer; Gerald Friedland; John Matts; Carroll Child; Margaret Chesney
Journal:  Clin Infect Dis       Date:  2002-03-11       Impact factor: 9.079

3.  Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.

Authors:  S D Portsmouth; J Osorio; K McCormick; B G Gazzard; G J Moyle
Journal:  HIV Med       Date:  2005-05       Impact factor: 3.180

4.  A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.

Authors:  Constance A Benson; Charles van der Horst; Anthony Lamarca; David W Haas; Cheryl K McDonald; Corklin R Steinhart; John Rublein; Joseph B Quinn; Elsa Mondou; Franck Rousseau
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

5.  Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

Authors:  Joseph J Eron; Judith Feinberg; Harold A Kessler; Harold W Horowitz; Mallory D Witt; Felix F Carpio; David A Wheeler; Peter Ruane; Donna Mildvan; Bienvenido G Yangco; Richard Bertz; Barry Bernstein; Martin S King; Eugene Sun
Journal:  J Infect Dis       Date:  2004-01-07       Impact factor: 5.226

6.  Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression.

Authors:  Brian A Boyle; Dushyantha Jayaweera; Mallory D Witt; Kristy Grimm; Jen-fue Maa; Daniel W Seekins
Journal:  HIV Clin Trials       Date:  2008 May-Jun

7.  Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.

Authors:  Jean-Jacques Parienti; Véronique Massari; Diane Descamps; Astrid Vabret; Elisabeth Bouvet; Bernard Larouzé; Renaud Verdon
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

8.  Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence.

Authors:  Valerie E Stone; Jamie Jordan; Jerry Tolson; Robert Miller; Tom Pilon
Journal:  J Acquir Immune Defic Syndr       Date:  2004-07-01       Impact factor: 3.731

9.  Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

Authors:  Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

10.  Estimating the mean and variance from the median, range, and the size of a sample.

Authors:  Stela Pudar Hozo; Benjamin Djulbegovic; Iztok Hozo
Journal:  BMC Med Res Methodol       Date:  2005-04-20       Impact factor: 4.615

View more
  79 in total

1.  Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients.

Authors:  A Buscher; C Hartman; M A Kallen; T P Giordano
Journal:  Int J STD AIDS       Date:  2012-05       Impact factor: 1.359

2.  Recent key advances in human immunodeficiency virus medicine and implications for China.

Authors:  Kai Sun; Shuntai Zhou; Ray Y Chen; Myron S Cohen; Fujie Zhang
Journal:  AIDS Res Ther       Date:  2010-05-26       Impact factor: 2.250

3.  Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.

Authors:  Wasana Prasitsuebsai; Sirinya Teeraananchai; Thida Singtoroj; Khanh Huu Truong; Jintanat Ananworanich; Viet Chau Do; Lam Van Nguyen; Pope Kosalaraksa; Nia Kurniati; Tavitiya Sudjaritruk; Kulkanya Chokephaibulkit; Stephen J Kerr; Annette H Sohn
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

4.  A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.

Authors:  David R Bangsberg; Kathleen Ragland; Alex Monk; Steven G Deeks
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

5.  Optimizing initial therapy for HIV infection.

Authors:  Mark W Hull; Julio S G Montaner
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

6.  Accumulated pre-switch resistance to more recently introduced one-pill-once-a-day antiretroviral regimens impacts HIV-1 virologic outcome.

Authors:  Rebecca Reece; Allison Delong; D'Antuono Matthew; Karen Tashima; Rami Kantor
Journal:  J Clin Virol       Date:  2018-05-21       Impact factor: 3.168

7.  Impact of mail order pharmacy use and travel time to pharmacy on viral suppression among people living with HIV.

Authors:  Jessica P Ridgway; Eleanor E Friedman; Justine Choe; Cynthia T Nguyen; Todd Schuble; Natasha N Pettit
Journal:  AIDS Care       Date:  2020-05-04

8.  Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women.

Authors:  David B Hanna; Nancy A Hessol; Elizabeth T Golub; Jennifer M Cocohoba; Mardge H Cohen; Alexandra M Levine; Tracey E Wilson; Mary Young; Kathryn Anastos; Robert C Kaplan
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

Review 9.  Pharmacotherapy of pediatric HIV infection.

Authors:  Natella Rakhmanina; B Ryan Phelps
Journal:  Pediatr Clin North Am       Date:  2012-08-22       Impact factor: 3.278

10.  Women, Aging, and HIV: Clinical Issues and Management Strategies.

Authors:  Julie A Womack; Cynthia A Brandt; Amy C Justice
Journal:  J Nurse Pract       Date:  2014-06-01       Impact factor: 0.767

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.